Xenon Pharmaceuticals (XENE) Reports In-Line Q3 EPS

Xenon Pharmaceuticals (NASDAQ: XENE) reported Q3 EPS of ($1.15), in-line with the analyst estimate of ($1.15). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• S&P Global (SPGI) Declares $0.97 Quarterly Dividend; 1% Yield
• Rocket Lab launches U.S. Space Force mission in record 16 hours